000			01732 a2200457 4500
005			20250514052507.0
264		0	_c20030411
008			200304s 0 0 eng d
022			_a0114-5916
024	7		_a10.2165/00002018-200225150-00002 _2doi
040			_aNLM _beng _cNLM
100	1		_aLangebrake, Claudia
245	0	0	_aMinimising the long-term adverse effects of childhood leukaemia therapy. _h[electronic resource]
260			_bDrug safety _c2002
300			_a1057-77 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAlkylating Agents _xadverse effects
650	0	4	_aAnthracyclines _xadverse effects
650	0	4	_aAntimetabolites _xadverse effects
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAsparaginase _xadverse effects
650	0	4	_aAsparagine _xadverse effects
650	0	4	_aCardiovascular Diseases _xchemically induced
650	0	4	_aChild
650	0	4	_aClinical Trials as Topic
650	0	4	_aGlucocorticoids _xadverse effects
650	0	4	_aGonadal Disorders _xchemically induced
650	0	4	_aHumans
650	0	4	_aLeukemia _xdrug therapy
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aOsteonecrosis _xchemically induced
650	0	4	_aPodophyllotoxin _xadverse effects
650	0	4	_aPolyethylene Glycols _xadverse effects
650	0	4	_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy
650	0	4	_aTretinoin _xadverse effects
650	0	4	_aVinca Alkaloids _xadverse effects
700	1		_aReinhardt, Dirk
700	1		_aRitter, Jörg
773	0		_tDrug safety _gvol. 25 _gno. 15 _gp. 1057-77
856	4	0	_uhttps://doi.org/10.2165/00002018-200225150-00002 _zAvailable from publisher's website
999			_c12258956 _d12258956